Peroxisome proliferator-activated receptors (PPARs) as therapeutic target in neurodegenerative disorders

• Published in: Biochemical and biophysical research communications 2017-02, Vol.483 (4), p.1166-1177
• Main Authors: Agarwal, Swati, Yadav, Anuradha, Chaturvedi, Rajnish Kumar
• Format: Article
• Language: English
• Subjects: 60 APPLIED LIFE SCIENCES; ANIMALS; Calcium - metabolism; DRUGS; Homeostasis; Humans; IN VITRO; IN VIVO; INFLAMMATION; Inflammation - metabolism; MITOCHONDRIA; Mitochondria - metabolism; Mitochondrial biogenesis; Mitochondrial dynamics; Mitochondrial dysfunction; NERVOUS SYSTEM DISEASES; Neurodegenerative Diseases - metabolism; Neurodegenerative Diseases - pathology; Neurodegenerative Diseases - therapy; Neurodegenerative disorder; OXIDATION; Oxidative Stress; PATHOGENESIS; Peroxisome Proliferator-Activated Receptors - drug effects; Peroxisome Proliferator-Activated Receptors - metabolism; PGC-1 alpha; Pioglitazone; POTENTIALS; RECEPTORS; REVIEWS; Rosiglitazone; STRESSES
• ISSN: 0006-291X; 1090-2104
• DOI: 10.1016/j.bbrc.2016.08.043

Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors and they serve to be a promising therapeutic target for several neurodegenerative disorders, which includes Parkinson disease, Alzheimer's disease, Huntington disease and Amyotrophic Lateral Sclerosis. PPARs play an important role in the downregulation of mitochondrial dysfunction, proteasomal dysfunction, oxidative stress, and neuroinflammation, which are the major causes of the pathogenesis of neurodegenerative disorders. In this review, we discuss about the role of PPARs as therapeutic targets in neurodegenerative disorders. Several experimental approaches suggest potential application of PPAR agonist as well as antagonist in the treatment of neurodegenerative disorders. Several epidemiological studies found that the regular usage of PPAR activating non-steroidal anti-inflammatory drugs is effective in decreasing the progression of neurodegenerative diseases including PD and AD. We also reviewed the neuroprotective effects of PPAR agonists and associated mechanism of action in several neurodegenerative disorders both in vitro as well as in vivo animal models. •Peroxisome -activated receptors (PPARs) serve to be a promising therapeutic target for several neurodegenerative disorders.•PPAR agonist as well as provides neuroprotection in vitro as well as in vivo animal models of neurodegenerative disorders.•PPAR activating anti-inflammatory drugs use is effective in decreasing progression of neurodegenerative diseases.